"ErbB Receptors" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A family of structurally-related cell-surface receptors that signal through an intrinsic PROTEIN-TYROSINE KINASE. The receptors are activated upon binding of specific ligands which include EPIDERMAL GROWTH FACTORS, and NEUREGULINS.
| Descriptor ID |
D066246
|
| MeSH Number(s) |
D08.811.913.696.620.682.725.400.009 D12.776.543.750.630.009 D12.776.543.750.750.400.074
|
| Concept/Terms |
ErbB Receptors- ErbB Receptors
- Receptors, ErbB
- Receptors, Epidermal Growth Factor-Urogastrone
- Receptors, Epidermal Growth Factor Urogastrone
- Receptors, Epidermal Growth Factor
- EGF Receptors
- Receptors, EGF
- Epidermal Growth Factor Receptor Family Proteins
- HER Family Receptors
- Family Receptors, HER
- Receptors, HER Family
- Erb-b2 Receptor Tyrosine Kinases
- Erb b2 Receptor Tyrosine Kinases
|
Below are MeSH descriptors whose meaning is more general than "ErbB Receptors".
Below are MeSH descriptors whose meaning is more specific than "ErbB Receptors".
This graph shows the total number of publications written about "ErbB Receptors" by people in this website by year, and whether "ErbB Receptors" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2009 | 1 | 0 | 1 |
| 2019 | 0 | 2 | 2 |
To return to the timeline,
click here.
Below are the most recent publications written about "ErbB Receptors" by people in Profiles.
-
Epidermal Growth Factor Receptor Blockade in Head and Neck Cancer: What Remains? J Clin Oncol. 2019 11 01; 37(31):2807-2814.
-
Identifying Resistance Mechanisms to Osimertinib via Blood Biopsy. Clin Lung Cancer. 2019 11; 20(6):e597-e600.
-
Using whole genome amplification (WGA) of low-volume biopsies to assess the prognostic role of EGFR, KRAS, p53, and CMET mutations in advanced-stage non-small cell lung cancer (NSCLC). J Thorac Oncol. 2009 Jan; 4(1):12-21.
-
Phosphoinositol phosphatase SHIP2 promotes cancer development and metastasis coupled with alterations in EGF receptor turnover. Carcinogenesis. 2008 Jan; 29(1):25-34.